HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer

[podsart]

Wondering what the group members thought of this and any resultant actionable current implications?

Hope the link below works

“Key Points

Question Does inheritance of the adrenal-permissive HSD3B1(1245C) allele indicate probable worse clinical outcomes in men treated with androgen deprivation therapy with or without docetaxel for metastatic castration-sensitive prostate cancer?

Findings In this study including 475 genotyped white men with metastatic prostate cancer treated in the E3805 Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer trial, the adrenal-permissive genotype (ie, inheritance of ≥1 HSD3B1[1245C] allele) was associated with significantly shorter time to castration-resistant disease and significantly lower overall survival in men with low-volume disease. There was no association between genotype and outcomes in men with high-volume disease.

Meaning The adrenal-permissive genotype is associated with inferior outcomes in low-volume metastatic prostate cancer and may help identify patients who could benefit from escalated therapy.”

jamanetwork.com/journals/ja...

[j-o-h-n]

Sorry, above my pay grade...

Good Luck, Good Health and Good Humor.

j-o-h-n Wednesday 05/13/2020 7:41 PM DST